NCT03022552Recruiting
Heart Attack Research Program: Platelet Sub-Study (HARP)
Heart Attack Research Program: Platelet Sub-Study (HARP); Platelet Collection for Patients With Myocardial Infarction
Source: ClinicalTrials.gov · Last updated 20 Apr 2026
Brief summary (registry, in English)
This prospective observational cohort study, will investigate the platelet phenotype, platelet genetic composition, and role of platelets as effector cells in women and men with myocardial infarction (MINOCA or MI-CAD) and controls. This study, which will take place at NYU and Bellevue Medical Center, and participating external sites. May have concurrent enrollment with the HARP Main Imaging (NCT02914483). Additionally, a sex, group of age and race matched disease controls 'CATH-NOCA' composed of women and men with stable angina referred for cardiac catheterization, will be enrolled. Blood obtained during the initial catheterization and 2 months post-MI will be utilized for platelet testing.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 350 (estimated)
- First submitted
- 13 Jan 2017
- Start date
- 1 Jul 2020
- Primary completion date
- 30 Jun 2027
- Lead sponsor
- NYU Langone Health
- Diseases
- Coronary artery disease
- NCT number
- NCT03022552
What you commit to
- Study type: Observational
- Planned participants: 350
- From 1 Jul 2020 to the primary completion date, 30 Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Thrombolytic therapy for STEMI (qualifying event)
- Use of any of the following medications:
Other illness
- Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma
Lab values
- Platelet antagonists (except aspirin and thienopyridines) within 7 days
- Thrombocytopenia (platelet count \<100,000)
- Thrombocytosis (platelet count \>500,000)
- Anemia (hemoglobin \<9 mg/dl)
Other
- Recent use of vasospastic agents, such as cocaine, triptans, or ergot alkaloids (≤1 month)
- Pregnancy
- NSAIDs (e.g., ibuprofen, naproxen) within 3 days.
- Hemorrhagic diathesis
Who the study is looking for
- Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
- Objective evidence of MI (either or both of the following):
- Elevation of troponin to above the laboratory upper limit of normal (ULN)
- ST segment elevation of ≥1mm on 2 contiguous ECG leads
- Willing to provide informed consent and comply with all aspects of the protocol
- Administration of aspirin at least 1 hour before cardiac catheterization
- Administration of thienopyridine (e.g., clopidogrel, ticagrelor) at least 1 hour before cardiac catheterization
- Women and men with ≥50% of any major epicardial vessel on invasive angiography may participate
Age in the registry: 21 years to 99 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| NYU Langone Medical Center Coordinator of this site? Confirm its status | New York | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.